TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26461821
Drug: Crisaborole topical
Normalized name: crisaborole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole topical ointment, 2%
Study: 9400905
Drug: Acebutolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (100 mg twice daily)
Study: 9400905
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg slow-release twice daily)
Study: 26468478
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg twice daily)
Study: 8101300
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 mg twice daily)
Study: 8101300
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 mg per day)
Study: 8101300
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (desired prothrombin time range 2.8-4.8 international normalised ratio)
Study: 6875209
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (400 mg/day for one month)
Study: 24401481
Drug: Ologen™ implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ologen™ implant (OLO)
Study: 17503753
Drug: Dietary uridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary uridine supplement (36 g three times a day for 10 consecutive days/month)
Study: 15474756
Drug: E2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 levels >= 20 pmol/l
Study: 15474756
Drug: E2 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 levels < 20 pmol/l
Study: 10776469
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Study: 10776469
Drug: Cefuroxime (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (750 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Study: 10776469
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg i/v post operatively, 12 hourly for 2 days followed by oral 500 mg twice daily for 3 days), n = 35
Study: 10776469
Drug: No antibiotic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic, n = 30
Study: 1655220
Drug: Edatrexate (10‐EdAM)
Normalized name: edamine
DrugBank: Ethylenediamine (DB14189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edatrexate (10‐EdAM) 80 mg/m2, Cyclophosphamide 800 mg/m2, Cisplatin 80 mg/m2 on day 1, repeated every 3 weeks
Study: 1655220
Drug: Edatrexate (10‐EdAM)
Normalized name: edamine
DrugBank: Ethylenediamine (DB14189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edatrexate (10‐EdAM) 70 mg/m2, Cyclophosphamide 700 mg/m2, Cisplatin 70 mg/m2 on day 1, repeated every 3 weeks
Study: 1655220
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose schedule
Study: 6304513
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 X 10(6) units intramuscularly before transplant, then three times a week for six weeks and twice a week for eight weeks, total of 102 X 10(6) units)
Study: 20025679
Drug: Low-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose i.v. iron therapy (LD-IVIT) - <or=50 mg/week of iron sucrose
Study: 20025679
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy (OIT)
Study: 20025679
Drug: Low-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose i.v. iron therapy (LD-IVIT)
Study: 16542286
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg infusion every 6 h
Study: 16542286
Drug: CIM 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIM 400 mg infusion every 12 h
Study: 16542286
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg infusion every 12 h
Study: 12767502
Drug: Intrathecal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal triamcinolone acetonide (TCA) administration (6 administrations every third day)
Study: 12767502
Drug: Continued intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued intrathecal TCA treatment (1 injection every 6 to 12 weeks)
Study: 9379341
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin 20 mg/m2/day i.v. for 3 days and etoposide 100 mg/m2/day i.v. for 3 days)
Study: 9379341
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus melatonin
Study: 8268648
Drug: Sequential ultrafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ultrafiltration (UF) with constant dialysate Na (140 mEq/L)
Study: 8268648
Drug: Sequential ultrafiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ultrafiltration (UF) with varying dialysate Na (150 mEq/L in the first hour, 142 in the second, and 137 in the third)
Study: 3890131
Drug: L-carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine administration (2 g i.v. three times weekly for 6 weeks)
Study: 31409331
Drug: T33 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: T33 (0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Study: 31409331
Drug: T33 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: T33 (2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Study: 31409331
Drug: T33 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: T33 (200 mg/kg and 600 mg/kg)
Study: 27402551
Drug: ASSIST administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASSIST administered via ACASI
Study: 24709256
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily for 12 weeks with PegIFN/RBV
Study: 24709256
Drug: Faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 120 mg once daily for 24 weeks with PegIFN/RBV
Study: 24709256
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (12-week and 24-week) received identical treatment from weeks 2 to 12
Study: 17913317
Drug: Propofol 0.5mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5mg/kg plus dexamethasone 8 mg
Study: 15914508
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.8 g/kg; LP)
Study: 15914508
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein diet (1.8 g/kg; MP)
Study: 15914508
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (3.6 g/kg; HP)
Study: 10229559
Drug: Iloprost i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost i.v. infusion up to 2 ng/Kg/min for 6/h/day for 28 days (Group A)
Study: 10229559
Drug: Iloprost i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost i.v. infusion up to 1.5 ng/Kg/min for 16/h/day for 7 days (Group B)
Study: 7913730
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of zidovudine daily
Study: 7913730
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of zidovudine daily
Study: 2493733
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (2 mg/kg/10 minutes)
Study: 2493733
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg/1 minute)
Study: 17655565
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (YT)
Study: 25289715
Drug: Creatine (Cr;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (Cr; 5 g creatine plus 5 g maltodextrose)
Study: 25289715
Drug: Beta-alanine plus
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine plus creatine (β‐ALA+Cr; 1.6 g beta alanine plus 5 g creatine plus 3.4 g maltodextrose)
Study: 25289715
Drug: Beta-alanine (β‐ALA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (β‐ALA; 1.6 g beta alanine plus 8.4 g maltodextrose)
Study: 25289715
Drug: Placebo (P;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P; 10 g maltodextrose)
Study: 24239154
Drug: Standard cardiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardiological therapy only
Study: 11129744
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 mL Cerebrolysin in 100 mL physiologic saline IV) once a day from Monday to Friday for 4 weeks
Study: 9053827
Drug: Calcium-enriched group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-enriched group (1200 mg RDA)
Study: 9053827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (728 mg calcium)
Study: 1645047
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A (original piroxicam)
Study: 1645047
Drug: Drug B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug B (generic piroxicam)
Study: 1645047
Drug: Drug C
Normalized name: Drug coating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug C (another generic piroxicam)
Study: 1645047
Drug: Chronic disease
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic disease treatment
Study: 27323902
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles carboplatin-olaparib followed by olaparib monotherapy 300 mg BID
Study: 27323902
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 BID day 1-14 q day 22
Study: 23870160
Drug: 2-dose methylprednisolone
Normalized name: methylprednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose methylprednisolone (30 mg/kg per dose, given 8 hours preoperatively and operatively)
Study: 23870160
Drug: Single-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose methylprednisolone (30 mg/kg per dose, given operatively)
Study: 23870160
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (2-dose and single-dose)
Study: 23870160
Drug: 2-dose methylprednisolone
Normalized name: methylprednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose methylprednisolone
Study: 23870160
Drug: Single-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose methylprednisolone
Study: 23446065
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CBT + milnacipran 100 mg/d)
Study: 21097770
Drug: Supplemental parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental parenteral glutamine
Study: 18426835
Drug: Elevated serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated serum parathyroid hormone (PTH) levels (> or =63 ng/l, IV quartile cut point)
Study: 18426835
Drug: Elevated serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated serum parathyroid hormone (PTH) levels after controlling for age, gender, co-morbidity, and creatinine
Study: 12926103
Drug: YM511 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM511 0.3 mg/day
Study: 12926103
Drug: YM511 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM511 (all doses)
Study: 6643335
Drug: Cefoperazone 2
Normalized name: cefoperazone 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 2 g intravenous infusion over 15 min
Study: 29038234
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg subcutaneous every 4 weeks for 16 weeks (DB)
Study: 29038234
Drug: Lanreotide during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide during DB and IOL treatment
Study: 29038234
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during DB and IOL treatment
Study: 24142804
Drug: Molsidomine (Coruno®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (Coruno® 16 mg, once daily)
Study: 22865782
Drug: Exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (EXE) treatment
Study: 12573372
Drug: Intrahepatic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic arterial (IHA) chemotherapy (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 mins and 22‐h infusion 1600 mg/m2, day 1 and 2, repeated every 14 days)
Study: 12573372
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg/m2 and 22‐h infusion 600 mg/m2, day 1 and 2, repeated every 14 days)
Study: 12573372
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (IHA and intravenous)
Study: 10386280
Drug: Granisetron‐Droperidol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron‐Droperidol combination
Study: 1920171
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of heart failure
Study: 29989335
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla300)
Study: 29947060
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (Deg)
Study: 23141150
Drug: M9L10 (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: M9L10 (melphalan 9 mg/m²/d and lenalidomide 10 mg/d)
Study: 23141150
Drug: M6L10 (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: M6L10 (melphalan 6 mg/m²/d and lenalidomide 10 mg/d)
Study: 23141150
Drug: M4L15 (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: M4L15 (melphalan 4 mg/m²/d and lenalidomide 15 mg/d)
Study: 23141150
Drug: M5L10 (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: M5L10 (melphalan 5 mg/m²/d and lenalidomide 10 mg/d)
Study: 16466606
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg and 40 mg
Study: 9042047
Drug: Cinalukast 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinalukast 10 mg
Study: 9042047
Drug: Cinalukast 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinalukast 50 mg
Study: 9042047
Drug: Cinalukast 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinalukast 200 mg
Study: 7874603
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (42 micrograms/nostril) administered three times a day for 8 weeks
Study: 7874603
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a day for 8 weeks
Study: 24149180
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cediranib (20 mg)
Study: 20180668
Drug: Osmotic-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic-release methylphenidate combined with cognitive-behavioral therapy
Study: 20180668
Drug: Existing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatment program sources (treatment program staff, social services, juvenile justice system, mental health clinics)
Study: 7871046
Drug: 0.28 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.28 g/kg alcohol
Study: 7871046
Drug: 0.36 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.36 g/kg alcohol
Study: 7871046
Drug: 0.54 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.54 g/kg alcohol
Study: 7871046
Drug: 0.72 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.72 g/kg alcohol
Study: 21708838
Drug: 0.00 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.00 g/kg (placebo)
Study: 7871046
Drug: Higher alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher alcohol doses
Study: 27061779
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg) administered at 01:00, 03:00, 05:00, and 07:00 on both nights (total of 800 mg/night)
Study: 27061779
Drug: Placebo gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gum administered at 01:00, 03:00, 05:00, and 07:00 on both nights
Study: 25499937
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg self-administered via single 1 mL prefilled pen every 2 weeks (increased to 150 mg every 2 weeks at week 12 depending on LDL-C level)
Study: 25499937
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day (statin rechallenge)
Study: 22930768
Drug: Tapered OSSEOTITE
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered OSSEOTITE NT implants
Study: 22930768
Drug: Straight-walled OSSEOTITE
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight-walled OSSEOTITE implants
Study: 10506405
Drug: Ty21a enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a enteric-coated capsules (3 doses, every other day schedule)
Study: 10506405
Drug: Ty21a liquid
Normalized name: Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a liquid formulation (3 doses, every other day schedule)
Study: 8777997
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg orally)
Study: 8273531
Drug: Hypnotic doses
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic doses of propofol
Study: 2446752
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 at 3-week intervals)
Study: 2446752
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 at 3-week intervals) and Tamoxifen (10 mg twice per day)
Study: 26917606
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 μg twice daily
Study: 25691681
Drug: Sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric oxyhydroxide 1.0-3.0 g/day (2-6 tablets/day)
Study: 25691681
Drug: Sevelamer 2.4-14.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 2.4-14.4 g/day (3-18 tablets/day)
Study: 18258750
Drug: Taranabant (0.5-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant (0.5-600 mg)
Study: 18258750
Drug: Taranabant (0.5-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant (0.5-600 mg) with high-fat meal
Study: 17063345
Drug: Sibutramine in
Normalized name: Product containing sibutramine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine in combination with diet and lifestyle advice
Study: 10570622
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg, 2 to 10 times daily) coadministered with levodopa/carbidopa or levodopa/benserazide
Study: 2745343
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl infusion (mean volume 1,280.3 +/- 107.3 ml)
Study: 333077
Drug: Liberal sodium
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal sodium bicarbonate treatment (5 to 15 mEq bicarbonate/dl 10% glucose)
Study: 333077
Drug: Restricted sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted sodium bicarbonate treatment
Study: 31370154
Drug: FFE-50× at
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFE-50× at 200 mg
Study: 31370154
Drug: FFE-10× at
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFE-10× at 1200 mg
Study: 31370154
Drug: FFE-50× at
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFE-50× at 100 mg
Study: 31370154
Drug: FFE-10× at
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFE-10× at 600 mg
Study: 28365118
Drug: Moderate grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 3 days (MGD3)
Study: 28365118
Drug: Moderate grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 7 days (MGD7)
Study: 28365118
Drug: Moderate grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 14 days (MGD14)
Study: 28365118
Drug: Moderate grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement) for 21 days (MGD21)
Study: 28365118
Drug: Moderate grain
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate grain diet (MGD; 50% chopped grass hay, 42% rolled barley grain, and 8% mineral and vitamin supplement)
Study: 28365118
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (CTRL; 92% chopped grass hay and 8% mineral and vitamin supplement on a dry matter basis)
Study: 25262164
Drug: Chemo-immunotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-immunotherapy (group A)
Study: 19702088
Drug: Chemotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (group B)